Dr. Reddys Laboratories Ltd.

Foreign Institutional Investors (FIIs) have raised their stake in Dr Reddy’s Laboratories, an integrated global pharmaceutical company to 34.30% at the end of March 2014 quarter from 33.35% as on December 31, 2013.

On the other hand, domestic institutional investors’ (DIIs) shareholding has decreased to 6.29% at the end of March 2014 quarter from 7.54% as on December 31, 2013. Under DIIs, mutual funds / UTI held maximum stake of 4.89%, followed by insurance companies (1.34 % stake) and Financial Institutions / Banks (0.06 stake).

Meanwhile, promoter and promoter group shareholding was unchanged at 25.52% at the end of March 2014 quarter.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.